Clinical Trial Update: Ibritumomab Tiuxetan (Zevalin)+ Rituximab Maintenance [Phase 2]

View source ↗

Summary

Phase 2 trial of ibritumomab tiuxetan (Zevalin) with rituximab maintenance in non-Hodgkin's lymphoma was terminated; results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Rituxan (rituximab)
• Zevalin (ibritumomab tiuxetan)
• ibritumomab tiuxetan (ibritumomab tiuxetan)

Snippet

Sponsor: University of Wisconsin, Madison | Conditions: Non-Hodgkin's Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2018-07-13